Minimal Residual Disease Testing Market Insights On Growth Drivers, Trends, And Opportunities
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Minimal Residual Disease Testing Market From 2026 To 2030?
The minimal residual disease testing market has experienced substantial expansion in recent years. It is projected to increase from $1.8 billion in 2025 to $2.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.5%. The historical growth of this market can be attributed to the rising prevalence of hematological malignancies, advancements in molecular diagnostic technologies, heightened awareness about minimal residual disease, increased adoption of precision medicine, and supportive government healthcare initiatives.
The minimal residual disease testing market is projected to experience substantial expansion in the coming years. It is anticipated to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period can be attributed to factors such as technological progress in nGS and digital PCR, increased funding for cancer research, growing partnerships between diagnostic and pharmaceutical firms, the escalating need for personalized treatment oversight, and the development of healthcare infrastructure in emerging markets. Key trends anticipated for this period encompass the widespread adoption of liquid biopsy, customized cancer monitoring, enhancements in early detection and prognosis, the incorporation of molecular diagnostics, and the broadening of oncology research.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Which Key Factors Are Driving The Minimal Residual Disease Testing Market Growth?
The escalating incidence of cancer is projected to propel the expansion of the minimal residual disease testing market moving forward. Cancer describes a state where certain body cells multiply uncontrollably and spread to other areas of the body. Minimal residual disease testing, a highly sensitive technique for identifying cancer cells in the human body, is primarily utilized for detecting cancer stages. This capability assists cancer patients in preventing the disease at an early stage, thereby boosting the minimal residual disease testing market. For instance, in January 2023, the National Institutes of Health (NIH), a U.S.-based government agency, reported that 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the United States during 2023. Consequently, the increasing prevalence of cancer is a significant driver for the growth of the minimal residual disease testing market.
How Is The Minimal Residual Disease Testing Market Organized By Segment Classification?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
What Trends Are Transforming The Minimal Residual Disease Testing Market?
Leading firms within the minimal residual disease testing market are introducing cancer research testing solutions designed to boost detection sensitivity, refine treatment monitoring, and further precision medicine strategies for improved patient results. The IDT Archer FUSIONPlex Core Solid Tumor Panel is a targeted next-generation sequencing assay employed for identifying gene fusions and mutations in solid tumors, thereby supporting precision oncology and choices regarding treatment. For example, in April 2023, Integrated DNA Technologies (IDT), a US-based genomic solutions provider, introduced the IDT Archer FUSIONPlex Core Solid Tumor Panel, an improved cancer research testing solution that now provides broadened and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay streamlines the detection of fusions and variant calling in solid tumors, requiring only a single sample input and presenting researchers with a scalable, user-friendly option that conserves time, resources, and expenses.
Who Are The Industry Participants Involved In The Minimal Residual Disease Testing Market?
Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Get The Full Minimal Residual Disease Testing Market Report:
Which Region Is The Leading Market For The Minimal Residual Disease Testing Market?
North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Minimal Residual Disease Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Minimal Residual Disease Testing Market 2026, By The Business Research Company
Minimal Residual Disease Testing Market Report 2026
Rare Disease Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Infectious Disease Diagnostics Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
